Pando Software Begins Pre-Registration of Three New P2E Pandonia Universes
28.4.2022 07:24:00 EEST | Business Wire | Press release
The new P2E Pandonia Universe starts pre-registration ahead of its simultaneous worldwide release. The three Pandonia Universes include ‘Pandonia Arena,’ ‘Guardians of Pandonia,’ and ‘Dragons of Pandonia.’ Pre-registration is available now on https://pandonia.co.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006357/en/
Three new P2E Pandonia Universes have started pre-registration ahead of their worldwide release. The three Pandonia Universes include ‘Pandonia Arena,’ ‘Guardians of Pandonia,’ and ‘Dragons of Pandonia.’ Pre-registration is available now on the official website. (Graphic: Business Wire)
‘Pandonia Arena’ with unique heroes
‘Pandonia Arena’ was issued as non-fungible tokens (NFT) for heroes with distinctive visuals and unique skills. The control method that allows anyone to play easily, such as battle royale mode, big boss mode, and crown mode, is a huge advantage. The global No.1 Arcade NFT-based P2E game ‘Pandonia Arena’ will be released in May.
New collectible RPG, P2E game ‘Guardians of Pandonia’
‘Guardians of Pandonia’ is a mobile collectible RPG where you can create your own team with up to six characters and enjoy adventures, raids, and PvP content. In particular, there are high expectations for this new collectible P2E game in Japan, so it is planned to be released in June.
MMORPG 'Dragons of Pandonia,' a story created with a variety of dragons
‘Dragons of Pandonia’ is an MMORPG focused on dragons. It is the P2E-based MMORPG where users write their own huge and powerful stories relying on five different occupation types and various dragons. Development is underway aiming at a global launch in July.
Special benefits for pre-registrants of the three Pandonia Universes
For pre-registered users, Pando Software has announced that it will provide game-related privileges along with an airdrop event in which 10,000 mPANDO will be drawn and distributed, fitting the game's official release date.
In the three new Pandonia Universes, users can acquire mPANDO through gameplay as well as through other games currently being serviced by Pando Software. mPANDO is a MainNet coin and is designed to be used for various in-game applications.
Starting with the ‘Legend of Pandonia’ as its first P2E project in 2022, Pando Software has continued with the ‘I Love Pandonia’ release to the global market.
The detailed schedule and news about the three Pandonia Universes can be checked on the official website (https://pandonia.co).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006357/en/
Contact information
Pando Software Inc
Lucia Tanti
+82-70-5100-0815
pr@pandosoft.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom